natgillin/translations-raw huggingface dataset:
The full EPAR and risk management plan summary for Zontivity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Zontivity kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nearly all patients also took aspirin and/or another medicine to prevent atherothrombotic events, and were treated for at least a year. 
Peaaegu kõik patsiendid võtsid aterotrombootiliste tüsistuste ennetamiseks ka aspiriini ja/või muud ravimit ning ravi kestis vähemalt ühe aasta.
There are limited data on the use of Zontivity for longer than 2 years; therefore, after 2 years of treatment, the benefits and risks of Zontivity should be re-evaluated in individual patients by the treating doctor. 
Andmed Zontivity kasutamise kohta kauem kui 2 aastat on piiratud, seetõttu peab raviarst 2 aastat kestnud ravi järel uuesti hindama Zontivity kasulikkust ja riske igal patsiendil individuaalselt.
For patients with peripheral arterial disease, treatment with Zontivity may be started at any time. 
Perifeersete arterite haigusega patsientidel tohib alustada ravi Zontivityga mis tahes ajal.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Zontivity's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Inimravimite komitee otsustas, et Zontivity kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
What is Zontivity and what is it used for? 
Mis on Zontivity ja milleks seda kasutatakse?
Why is Zontivity approved? 
Miks Zontivity heaks kiideti?
It is not intended to provide practical advice on how to use Zontivity. 
Hindamisaruandes ei anta Zontivity kasutamise praktilisi nõuandeid.
It must also not be used in patients who have had intracranial haemorrhage (bleeding in the brain) or who are actively bleeding, nor in patients with severely reduced liver function. 
Samuti ei tohi seda kasutada patsiendid, kellel on olnud intrakraniaalne hemorraagia (ajuverejooks) või kellel on aktiivne verejooks, ega maksafunktsiooni raske kahjustusega patsiendid.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zontivity have been included in the summary of product characteristics and the package leaflet. 
Zontivity ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Heart attacks and some types of strokes result from blood clots in arteries. 
Südameinfarkte ja teatud tüüpi insulte põhjustavad arteriaalsed trombid.
The benefits of Zontivity were clearest in a group of 16,897 patients who had had a heart attack, but had no history of stroke or transient ischaemic attack (so-called ‘mini stroke'). 
Zontivity kasulikkus oli kõige ilmsem alarühmas, kus oli 16 897 patsienti, kellel oli varem olnud südameinfarkt, kuid mitte insult ega transitoorne isheemiline atakk (nn mini-insult).
Zontivity must not be used in patients who have had a stroke or mini stroke. 
Zontivityt ei tohi kasutada patsiendid, kellel on olnud insult või mini-insult.
What are the risks associated with Zontivity? 
Mis riskid Zontivityga kaasnevad?
This is a summary of the European public assessment report (EPAR) for Zontivity. 
See on ravimi Zontivity Euroopa avaliku hindamisaruande kokkuvõte.
In patients with peripheral arterial disease, the data showed a benefit for patients taking Zontivity, although the number of atherothrombotic events reported during the main study was not large enough to enable conclusive results. 
Ka perifeersete arterite haigusega patsientidel näitasid andmed Zontivity kasulikkust, kuid põhiuuringus teatatud aterotrombootiliste tüsistuste arv ei olnud lõplike järelduste tegemiseks piisav.
Zontivity contains the active substance vorapaxar. 
Zontivity sisaldab toimeainena vorapaksaari.
Thrombin is one of the substances involved in the clotting process, and when it attaches to the PAR-1 receptor it causes the platelets to become ‘sticky', helping the blood clot to form. 
Trombiin on hüübimises osalev aine; seondumisel PAR-1-retseptoriga muudab see trombotsüüdid n-ö kleepuvaks ja aitab nii verel hüübida.
For practical information about using Zontivity, patients should read the package leaflet or contact their doctor or pharmacist. 
Kui vajate Zontivity kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
Zontivity is available as tablets (2 mg) and can only be obtained with a prescription. 
Zontivity on retseptiravim ja seda turustatakse tablettidena (2 mg).
The most common side effect with Zontivity (which may affect up to 1 in 10 people) is bleeding, particularly nosebleed. 
Zontivity kõige sagedam kõrvalnäht (võib esineda 1 patsiendil 10st) on verejooks, eelkõige ninaverejooks.
Zontivity was compared with placebo (a dummy treatment) in a main study involving over 26,000 adults who had had a heart attack or other atherothrombotic event or who had peripheral arterial disease. 
Zontivityt võrreldi platseeboga (näiv ravim) ühes põhiuuringus, kus osales üle 26 000 südameinfarkti või muu aterotrombootilise tüsistuse või perifeersete arterite haiguse anamneesiga täiskasvanu.
Regarding Zontivity's safety profile, the CHMP was concerned about the risk of bleeding in patients taking Zontivity on top of their standard therapy, particularly serious bleeding which was more frequent in patients with a history of stroke. 
Mis puudutab Zontivity ohutusprofiili, siis väljendas inimravimite komitee ettevaatlikkust seoses verejooksu riskiga patsientidel, kes lisaks standardravile võtavad Zontivityt, eelkõige seoses raske verejooksuga, mida esines sagedamini insuldi anamneesiga patsientidel.
However, as patients with peripheral arterial disease have a high risk of atherothrombotic events and the treatment options for prevention of these events are limited, the CHMP considered that Zontivity's benefits are greater than its risks for this condition. 
Arvestades aga perifeersete arterite haigusega patsientidel esinevat suurt aterotrombootiliste tüsistuste riski ning olemasolevate ravivõimaluste piiratust, leidis inimravimite komitee, et Zontivity kasulikkus ületab riske ka sellel näidustusel.
It is given in combination with aspirin (acetylsalicylic acid) and where appropriate with a third medicine, clopidogrel, both of which also help prevent atherothrombotic events. 
Seda manustatakse koos aspiriiniga (atsetüülsalitsüülhape) ja vajaduse korral koos kolmanda ravimi klopidogreeliga, mis samuti aitavad aterotrombootilisi tüsistusi ära hoida.
In this group, 8.5% of patients (719 out of 8,458 patients) treated with Zontivity had an atherothrombotic event, compared with 10.3% of patients (867 out of 8,439 patients) on placebo. 
Selles rühmas oli aterotrombootiliste tüsistustega patsiente Zontivity uuringurühmas 8,5% (719 patsienti 8458st) ja platseeborühmas 10,3% (867 patsienti 8439st).
For more information about treatment with Zontivity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Zontivityga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
How does Zontivity work? 
Kuidas Zontivity toimib?
Vorapaxar blocks the PAR-1 receptors (known as ‘thrombin receptors') on the surface of the platelets. 
Vorapaksaar blokeerib trombotsüütide pinnal paiknevad PAR-1-retseptorid (trombiiniretseptorid).
It is given in combination with either aspirin or, where appropriate, with clopidogrel. 
Seda antakse kas koos aspiriini või vajadusel koos klopidogreeliga.
Among patients with peripheral arterial disease, 10.9% (177 out of 1,622 patients) taking Zontivity had an atherothrombotic event compared with 12.5% (206 out of 1,651 patients) of patients taking placebo. 
Perifeersete arterite haigusega patsiente, kellel esines aterotrombootilisi tüsistusi, oli Zontivity uuringurühmas 10,9% (177 patsienti 1622st) ja platseeborühmas 12,5% (206 patsienti 1651st).
The medicine has been shown to be beneficial in reducing the number of atherothrombotic events in patients who had had a heart attack. 
Ravimi kasulikkus aterotrombootiliste tüsistuste arvu vähendamisel südameinfarkti anamneesiga patsientidel on tõestatud.
Zontivity is a medicine used to reduce the occurrence of atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes in adult patients who have already had a heart attack or who have peripheral arterial disease (problem with blood flow in the arteries) with symptoms. 
Zontivity on ravim, mida kasutatakse aterotrombootiliste tüsistuste (trombidest ja arterite lubjastumisest põhjustatud probleemid), nt südameinfarktide või insultide esinemissageduse vähendamiseks südameinfarkti või perifeersete arterite haiguse (arteriverevoolu probleemi) anamneesiga täiskasvanud patsientidel.
How is Zontivity used? 
Kuidas Zontivityt kasutatakse?
Blocking the PAR-1 receptor stops the platelets becoming sticky, reducing the risk of a blood clot forming and helping to prevent a stroke or heart attack. 
PAR-1-retseptori blokeerimise tõttu ei kleepu trombotsüüdid kokku ja väheneb trombide tekkerisk, millega ennetatakse insulti või südameinfarkti.
Overall, 9.5% of patients (1,259 out of 13,225 patients) taking Zontivity had an atherothrombotic event compared with 10.7% (1,417 out of 13,224 patients) of patients taking placebo. 
Kokku oli patsiente, kellel esines aterotrombootilisi tüsistusi, Zontivity uuringurühmas 9,5% (1259 patsienti 13 225st) ja platseeborühmas 10,7% (1417 patsienti 13 224st).
It therefore considered it appropriate to restrict the use to patients who have not had a stroke. 
Seetõttu otsustas komitee, et ravimit tohivad võtta ainult patsiendid, kellel ei ole olnud insulti.
What benefits of Zontivity have been shown in studies? 
Milles seisneb uuringute põhjal Zontivity kasulikkus?
The main measure of effectiveness was based on the number of patients having an ‘event' such as a heart attack or stroke, or dying from cardiovascular disease (problems affecting the heart and blood vessels). 
Efektiivsuse põhinäitaja oli nende patsientide arv, kellel tekkis selline tüsistus, näiteks südameinfarkt või insult, või kes surid kardiovaskulaarse (südameveresoonkonna) haiguse tõttu.
For patients who have had a heart attack, treatment with Zontivity should start from 2 weeks after and preferably within one year of the occurrence of the heart attack. 
Ravi Zontivityga tuleb alustada vähemalt 2 nädalat pärast südameinfarkti (soovitatavalt kuni ühe aasta jooksul pärast infarkti).
Zontivity must not be used together with prasugrel or ticagrelor, two other medicines that help to prevent platelets from sticking together. 
Zontivityt ei tohi kasutada koos prasugreeli ega tikagrelooriga - ka need on toimeained, mis takistavad trombotsüütide kokkukleepumist.
Zontivity was more effective than placebo at reducing the occurrence of atherothrombotic events. 
Zontivity oli aterotrombootiliste tüsistuste esinemissageduse vähendamisel efektiivsem kui platseebo.
It is given in combination with aspirin and where appropriate, clopidogrel. 
Ravimit antakse koos aspiriiniga ja vajadusel koos klopidogreeliga.
The active substance in Zontivity, vorapaxar, is an inhibitor of platelet aggregation. 
Zontivity toimeaine vorapaksaar on trombotsüütide agregatsiooni inhibiitor, mis aitab ennetada trombide (soonesiseste verehüüvete) tekkimist.
Immediate Packaging 
Pakendi suuarus
EU/1/11/727/001 Xaluprine 20 mg/ml 
EU/1/11/727/001 Xaluprine
1 bottle + 1 bottle adaptor + 2 oral syringes 
1 pudel + 1 dosaator + 2 suusüstalt
Oral suspension Oral use bottle (glass); syringe (PET) 
Pudel (klaas); süstal (PET)
Strength Pharmaceutical Form 
Tugevus Ravimvorm Manustamisviis Pakendi iseloomustus
Packaging 
Suukaudne
EMEA Number (Invented) name 
(Väljamõeldud) nimetus
Hands and equipment should be washed and disinfected after use. 
Käed ja seadmed tuleb pärast kasutamist pesta ning desinfitseerida.
Protection starts at 3 weeks after vaccination and lasts until 60 weeks after vaccination. 
Kaitse algab 3 nädalat pärast vaktsineerimist ja kestab kuni 60 nädalat pärast vaktsineerimist.
The full EPAR for Evalon can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst Evaloni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Evalon is a vaccine. 
Evalon on vaktsiin.
The vaccine suspension should be diluted with the solvent and water according to dosing instructions and sprayed onto the birds so that each bird receives one dose. 
Vaktsiini suspensioon tuleb lahjendada lahusti ja veega annustusjuhiste järgi ning pihustada lindudele, nii et iga lind saab ühe annuse.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Evalon's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Veterinaarravimite komitee järeldas, et Evaloni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
It is also the time required after administration of a medicine before eggs may be used for human consumption. 
See on ka aeg, mis peab ravimi manustamisest mööduma, enne kui mune tohib tarvitada inimtoiduks.
This is a summary of the European public assessment report (EPAR) for Evalon. 
See on vaktsiini Evalon Euroopa avaliku hindamisaruande kokkuvõte.
This will help protect against coccidiosis. 
See aitab kaitsta linde koktsidioosi eest.
The withdrawal period for meat and eggs from chickens treated with Evalon is ‘zero' days, which means there is no mandatory waiting time. 
Evaloniga ravitud kanade liha ja munade keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
The results with Evalon and the comparator vaccine were similar for 3 out 4 farms; on 1 farm Evalon vaccinated chickens showed better protection than those given the comparator. 
Evaloni ja võrdlusvaktsiini tulemused sarnanesid 3 farmis 4st; 1 farmis esines Evaloniga vaktsineeritud kanadel parem kaitse kui võrdlusvaktsiini saanud kanadel.
In the future if the animals are exposed to the same Eimeria species the immune system will be able to respond more quickly. 
Kui linnud puutuvad hiljem samade Eimeria liikidega uuesti kokku, reageerib immuunsüsteem kiiremini.
What is Evalon and what is it used for? 
Mis on Evalon ja milleks seda kasutatakse?
Why is Evalon approved? 
Miks Evalon heaks kiideti?
Coccidiosis is a disease of the gut which results in reduced growth, severe diarrhoea, reduced egg production and a high death rate. 
Koktsidioos on soolehaigus, mis põhjustab kasvupeetust, rasket kõhulahtisust, vähenenud munatoodangut ja suurt suremust.
It is not intended to provide practical advice on how to use Evalon. 
Hindamisaruandes ei anta Evaloni kasutamise praktilisi nõuandeid.
Evalon is a veterinary vaccine to protect chickens against coccidiosis caused by the coccidia parasites Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix and Eimeria tenella. 
Evalon on veterinaarvaktsiin kanade kaitsmiseks koktsidioosi eest, mida põhjustavad koktsiidparasiidid Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix ja Eimeria tenella.
The vaccine solvent contains the adjuvant montanide IMS to enhance the immune response. 
Vaktsiini lahusti sisaldab immuunvastuse tugevdamiseks adjuvanti montaniid IMS.
The vaccine contains the oocysts of Eimeria species that have been weakened so that they cannot cause disease. 
Vaktsiin sisaldab parasiidi Eimeria mitme liigi ootsüste, mida on nõrgestatud, et need ei põhjustaks haigust.
In a field study involving 4 farms, shedding of oocysts in the faeces was reduced within 3 weeks of vaccination both in Evalon vaccinated chicks and those vaccinated with another vaccine against Eimeria. 
4 farmis toimunud väliuuringus vähenes ootsüstide eritumine väljaheitega 3 nädala jooksul pärast vaktsineerimist nii Evaloniga vaktsineeritud tibudel kui ka neil, keda vaktsineeriti Eimeria vastase muu vaktsiiniga.
Other information about Evalon? 
Muu teave Evaloni kohta
When Evalon is given to chickens, the animals' immune system recognises the Eimeria oocysts as foreign and makes defences against them. 
Kui kanadele manustatakse Evaloni, peab linnu immuunsüsteem Eimeria ootsüste võõraks ja tekitab nende vastu antikehi.
Evalon is available as a suspension and solvent and can only be obtained with a prescription. 
Evaloni turustatakse suspensiooni ja lahustina ning see on retseptivaktsiin.
What are the risks associated with Evalon? 
Mis riskid Evaloniga kaasnevad?
Infected birds shed disease spores (oocysts) in their faeces that can spread the infection. 
Nakatunud linnud eritavad haiguse spoore (ootsüste) väljaheitega, mis võib levitada nakkust.
The vaccine contains live attenuated (weakened) oocysts of Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix and Eimeria tenella. 
Vaktsiin sisaldab parasiitide Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix ja Eimeria tenella elusaid atenueeritud (nõrgestatud) ootsüste.
Safety information has been included in the summary of product characteristics and the package leaflet for Evalon, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Evaloni ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
For practical information about using Evalon, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Kui loomaomanikud või -pidajad vajavad Evaloni kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
The European Commission granted a marketing authorisation valid throughout the EU for Evalon on 
Euroopa Komisjon andis Evalonile müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 18/04/2016.
There are no known side effects with Evalon. 
Evalonil puuduvad teadaolevad kõrvaltoimed.
How does Evalon work? 
Kuidas Evalon toimib?
Evalon avian coccidiosis vaccine (live) 
Evalon lindude koktsidioosi elusvaktsiin
How is Evalon used? 
Kuidas Evaloni kasutatakse?
What benefits of Evalon have been shown in studies? 
Milles seisneb uuringute põhjal Evaloni kasulikkus?
The vaccine is given to one-day-old chicks by coarse spray vaccination. 
Vaktsiini manustatakse ühepäevastele tibudele jämespreina.
The birds consume the vaccine when preening their feathers. 
Linnud manustavad vaktsiini sulgede puhastamisel.
Pharmaceutical Form 
Tugevus Ravimvorm Manustamistee
Immediate Packaging Pack size blister (PVC/PVDC-Alu); wallet blister (PVC/PVDC-AluAlu); carton 
Õhukese polümeerikattega tabletid blister (PVC/PVDCAlu); blistritasku blister (PVC/PVDCAlu); karp
It is given once a day by slow infusion lasting about one hour. 
Ravimit manustatakse üks kord ööpäevas ligikaudu tund aega kestva aeglase infusioonina.
In patients between 12 months and 17 years of age, the dose depends on body surface area (calculated using the patient's height and weight). 
12-kuuste kuni 17-aastaste patsientide annus sõltub kehapindalast (arvutatakse patsiendi pikkuse ja kaalu alusel).
The full EPAR and risk management plan summary for Caspofungin Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Caspofungin Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In adults, treatment begins with a 70mg starting dose, followed by a daily dose of 50 mg, or of 70 mg if the patient weighs more than 80 kg. A lower dose is given to adults who have moderate problems with their liver. 
Täiskasvanutel algab ravi 70 mg algannusega, millele järgneb ööpäevane annus 50 mg või 70 mg, kui patsient kaalub üle 80 kg.
Caspofungin Accord should be used with caution in children below 12 months of age, because it has not been studied sufficiently in this age group. 
Caspofungin Accordi kasutamisel alla 12-kuustel lastel peab olema ettevaatlik, sest selles vanuserühmas ei ole ravimit piisavalt uuritud.
A risk management plan has been developed to ensure that Caspofungin Accord is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada Caspofungin Accordi võimalikult ohutu kasutamine.
What measures are being taken to ensure the safe and effective use of Caspofungin Accord? 
Mis meetmed võetakse, et tagada Caspofungin Accordi ohutu ja efektiivne kasutamine?
The company provided data from the published literature on caspofungin. 
Ettevõte esitas kaspofungiini kohta avaldatud kirjandusest pärinevad andmed.
The Committee recommended that Caspofungin Accord be approved for use in the EU. 
Komitee soovitas Caspofungin Accordi kasutamise Euroopa Liidus heaks kiita.
Caspofungin Accord caspofungin 
Caspofungin Accord kaspofungiin
Caspofungin Accord is an antifungal medicine used to treat adults, adolescents and children with: 
Caspofungin Accord on seenevastane ravim, millega ravitakse täiskasvanuid, noorukeid ja lapsi, kellel esineb:
Because Caspofungin Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Et Caspofungin Accord on geneeriline ravim, peetakse tema kasulikkust ja riske samasuguseks nagu võrdlusravimil.
No additional studies in humans were needed as Caspofungin Accord is a generic medicine that is given by infusion and contains the same active substance as Cancidas. 
Lisauuringuid ei olnud vaja, sest Caspofungin Accord on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui Cancidas.
Caspofungin Accord must be made up into a concentrated solution and then diluted before use, using a diluent that does not contain glucose. 
Caspofungin Accordist tuleb enne kasutamist valmistada kontsentreeritud lahus, kasutades lahjendit, mis ei sisalda glükoosi.
• invasive candidiasis (a type of fungal infection due to Candida); 
• invasiivne kandidoos (mikroseene Candida põhjustatud seennakkuse liik);
• invasive aspergillosis (another type of fungal infection due to Aspergillus) when the infection does not respond to or the patient does not tolerate amphotericin B or itraconazole (other antifungal medicines); 
• invasiivne aspergilloos (mikroseene Aspergillus põhjustatud seennakkuse liik) patsientidel, kellel amfoteritsiin B ja/või itrakonasool (teised seenevastased ravimid) on ebaefektiivsed või esineb nende suhtes talumatus;
This means that Caspofungin Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Cancidas. 
See tähendab, et Caspofungin Accord on sarnane võrdlusravimiga Cancidas, millel juba on Euroopa Liidus müügiluba.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Caspofungin Accord has been shown to be comparable to Cancidas. 
Inimravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Caspofungin Accord sarnane toime ravimiga Cancidas.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Caspofungin Accord, including the appropriate precautions to be followed by healthcare professionals and patients. 
Selle alusel lisati Caspofungin Accordi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
It is not intended to provide practical advice on how to use Caspofungin Accord. 
Hindamisaruandes ei anta Caspofungin Accordi kasutamise praktilisi nõuandeid.